Clinical Trials at Retina Northwest

Retina Northwest is committed to fostering cutting edge treatments for retinal diseases through our participation in clinical trials. Brief descriptions of our active clinical trials are listed below.  If you are a physician and have questions about any of our trials, or if you would like to refer a patient to our care, please contact our Clinical Research department at 503-274-2121.

Age-Related Macular Degeneration (AMD)

Atrophic (“Dry”)

APL2-GA-305 (Dry AMD)
Principal Investigator: Colin Ma, MD
Study Coordinator: Jessica Cardin
Active, Enrollment Closed

Gale: A phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan in subjects with geographic atrophy secondary to age-related macular degeneration.

ISEE2008 (Dry AMD)
Principal Investigator: Michael Lee, MD
Study Coordinator: Jessica Cardin
Active, Enrollment Closed

ISEE2008: A phase 3 multicenter, randomized, double-masked, shamcontrolled clinical trial to assess the safety and efficacy of intravitreal administration of Zimura™ (complement C5 inhibitor) in patients with geographic atrophy secondary to age-related macular degeneration.

Exudative (“Wet”)

Aerie (DME and Wet AMD)
Principal Investigator: Paul Tlucek MD
Study Coordinator: Brian Puckett
Active, Enrollment Pending

Phase 1/2a Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME).

GR42691 (Wet AMD)
Principal Investigator: Apurva Patel, MD
Study Coordinator: Brian Heimdahl
Active, Enrollment Closed

Avonelle-X: A multicenter long-term extension study designed to evaluate the long-term safety and tolerability of faricimab in patients with neovascular age-related macular degeneration.

Portal (Wet AMD)
Principal Investigator: Paul Tlucek, MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Enrollment Closed

A multicenter, open-label extension study to evaluate the long-term safety and tolerability of the port delivery system with ranibizumab in patients with Neovascular Age-Related Macular Degeneration.

20968 (Wet AMD)
Principal Investigator: Michael Lee, MD
Study Coordinator: Jessica Cardin
Active, Enrollment Closed

Pulsar: Randomized, Double-Masked, Active-Controlled, Phase 3 Study of the Efficacy and Safety of High Dose Aflibercept in Patients With Neovascular Age-Related Macular Degeneration.

Diabetic Eye Diseases

Diabetic Retinopathy

Principal Investigator: Paul Tlucek MD
Study Coordinator: Brian Puckett
Active, Currently Enrolling

Phase 1/2a Study of the Safety of AR-13503 Sustained Release Intravitreal Implant in Subjects with Neovascular Age-Related Macular Degeneration (nAMD) and Subjects with Diabetic Macular Edema (DME).

Principal Investigator: Apurva Patel MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Currently Enrolling

Randomized Trial of Intravitreous Aflibercept vs. Intravitreous Bevacizumab plus Aflibercept for Treatment for Central-Involved Diabetic Macular Edema.

Principal Investigator: Paul Tlucek MD
Study Coordinator: Ashley Adamo
Active, Currently Enrolling

A Pilot Study evaluating Photobiomodulation Therapy for Diabetic Macular Edema (Protocol AE).

Principal Investigator: Mark Peters, MD
Study Coordinator: Brian Puckett and Ashley Adamo
Active, Enrollment Closed

A Comparative Effectiveness Study of Intravitrela Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema Extension Study

KS301P104 (DME)
Principal Investigator: Apurva Patel, MD
Study Coordinator: Brian Heimdahl
Active, Enrollment Closed

Gleam: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).

Vein Occlusions

KS301P103 (RVO)
Principal Investigator: Apurva Patel, MD
Study Coordinator: Brian Heimdahl
Active, Enrollment Closed

Beacon: A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO).

GR41986 (CVO)
Principal Investigator: Apurva Patel, MD
Study Coordinator: Brian Heimdahl
Active, Enrollment Closed

Comino: A phase III, multicenter, randomized, double-masked, active comparator controlled study to evaluate the efficacy and safety of Faricimab in patients with macular edema secondary to central retinal or hemiretinal vein occlusion.

Macular Telangiectasia

Principal Investigator: Michael Lee, MD
Study Coordinator: Brian Puckett
Registry Only

A natural history observation and registry study of Macular Telangiectasia Type 2: The MacTel Study

Neurotech Macular Telangiecasia Surgical Study Phase 3

Principal Investigator: Michael Lee, MD
Study Coordinator: Brian Puckett
Active, Currently Enrolling

A phase III multicenter randomized, sham controlled, study to determine the safety and efficacy of Renexus in Macular Telangiectasia Type 2.

A Decrease font size. A Reset font size. A Increase font size.

 ATTENTION: ALL RETINA NORTHWEST PATIENTS

  For the health and safety of all patients and staff, note our current guidelines (subject to change without notice).

· NO PATIENTS WHO ARE ILL(fever, cough, runny nose or with any breathing symptoms) ARE ALLOWED INTO THE OFFICE

· During the injection process, MASKS ARE REQUIRED FOR PATIENTS AND ALL OTHERS IN THE PROCEDURE ROOM.

· PLEASE ARRIVE NO MORE THAN 5 MINUTES PRIOR TO YOUR APPOINTMENT. If you arrive early you may be asked to wait in your car until your appointment time.

· NO FAMILY MEMBER/FRIEND ALLOWED TO ACCOMPANY PATIENT (unless it is medically necessary)